Zenas Biopharma Inc (ZBIO) Stock Analysis
Verdict: HOLD
Aggressive insider buying at current support levels signals conviction ahead of a critical Q2 2026 FDA submission for obexelimab.
Investment score: 64/100
Analysis as of
Is Zenas Biopharma Inc stock worth reviewing? The TradeMates thesis
A speculative clinical-stage biotech buy supported by massive insider buying and an imminent FDA catalyst.
7-factor investment score
- Valuation: 50/100 (weight 20%)
- Financial Health: 45/100 (weight 15%)
- Technical Momentum: 40/100 (weight 15%)
- Earnings Quality: 35/100 (weight 15%)
- Insider Sentiment: 95/100 (weight 10%)
- Analyst Consensus: 85/100 (weight 10%)
- Risk-Adjusted Return: 55/100 (weight 15%)
Zenas Biopharma Inc opportunities and risks
What speaks for ZBIO
- Imminent FDA Submission Catalyst
What speaks against ZBIO
- Regulatory Approval Uncertainty
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| ZBIO | n/a | 0.0x | n/a | 0.0% | 0.0% | -27.5% |
| PVLA | n/a | 0.0x | n/a | 0.0% | 0.0% | -2.4% |
| PGEN | n/a | 38.2x | n/a | 75.6% | -647.0% | -9.7% |
| NVAX | n/a | 2.4x | n/a | 84.6% | -14.7% | -6.8% |
| KALV | n/a | 12.3x | n/a | 92.0% | -119.4% | -1.7% |
| SLS | n/a | 0.0x | n/a | 0.0% | 0.0% | -2.8% |
| Peer median | n/a | 2.4x | n/a | 75.6% | -14.7% | -2.8% |
Frequently asked questions about Zenas Biopharma Inc (ZBIO)
Is ZBIO stock a good investment?
The TradeMates model rates Zenas Biopharma Inc as HOLD with an investment score of 64/100. A speculative clinical-stage biotech buy supported by massive insider buying and an imminent FDA catalyst. This is algorithmic model output, not personal investment advice.
Is ZBIO stock a buy?
The TradeMates model verdict for ZBIO is HOLD with an investment score of 64/100. Treat this as a model signal to review, not a personal buy recommendation.